CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Risk factorsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug3402 patients receiving nasal high flow Wiki 1.00

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D011024 Pneumonia, Viral NIH 0.12
D011014 Pneumonia NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 RRisk Factors Worsening COVID19 (Coronavirus Infectious Disease 2019) for Outpatient With Home Monitoring (COVID-A-DOMEVA Study)

The main objective of the COVIDADOMEVA study is to identify the risk factors aggravating the COVID-19 (risk or protective factors), in out-patients suspected of being infected with precocious home monitoring. The primary event defining the aggravation will be then: hospitalization (medicine, resuscitation) or death. The studied potential risk factors will be mainly: - Socio-demographic: age, sex, place of residence or income - Comorbidities - Clinical signs: asthenia, dyspnea (kinetics)… - Drugs other than those related to the infection For this research project, this study needs to use the patient's data of the COVIDADOM cohort (patients suspected of being infected with SARS-CoV-2 with home monitoring) and will collect some supplementary data (clinical and biological). All these data will be integrated and analyzed in the PREDIMED clinical data lake platform (The implementation of PREDIMED has been approved by the French authority in terms of GDPR, CNIL, on October 10, 2019).

NCT04380662 Covid19 Other: Risk factors

Primary Outcomes

Description: The event defining the aggravation will be: hospitalization (medicine, resuscitation) or death The main potential risk factors will be the following: Socio-demographic: age, sex, place of residence, CSP and income. Comorbidities or aggravation: COPD, asthma, immunosuppression, or heart failure, diabetes imbalance, etc. Clinical signs: asthenia, dyspnea (kinetics), blood sugar, nutritional status, weight gain… Drugs other than those related to the infection and potential self-medication (anti-inflammatory, CEI, ARA…)

Measure: Identify the factors associated with the worsening of the COVID19

Time: 30 days

Secondary Outcomes

Description: Clinical and monitoring data of the the COVIDADOM cohort and of the COVIDADOMEVA case report form (CRF)

Measure: Describe the clinical care pathway of patients from Day 0 to Day 14

Time: 30 days

Description: Health status patient (stay at home, hospitalization or death)

Measure: Describe the health status at Day 30

Time: 30 days

Description: EQ5D-5L score

Measure: Describe the quality of life during the disease

Time: 30 days

No related HPO nodes (Using clinical trials)